KYMR
NASDAQKymera Therapeutics Inc.
News · 26 weeks129-37%
2026-03-012026-08-23
Mix6790d
- Insider27(40%)
- SEC Filings25(37%)
- Other8(12%)
- Leadership4(6%)
- Earnings2(3%)
- Analyst1(1%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Kymera Therapeutics Inc.SCHEDULE 13G/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 10-Q filed by Kymera Therapeutics Inc.10-Q - Kymera Therapeutics, Inc. (0001815442) (Filer)
- SECKymera Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
- PRKymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business UpdateEnrollment completed in KT-621 (STAT6) BROADEN2 Phase 2b AD trial nearly six months ahead of anticipated timeline, with data expected by year-end 2026 KT-621 Phase 3 trials in AD planned to initiate by mid-2027 KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-579 (IRF5) Phase 1 healthy volunteer trial ongoing, with data expected in 4Q26 KT-485 (IRAK4) Phase 1 trial commenced in healthy volunteers and HS patients by partner Sanofi Well-capitalized with $1.5 billion in cash as of June 30, 2026, and runway into 2029 Company to hold video conference call and webcast today at 8:30 a.m. ET WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -
- ANALYSTDeutsche Bank initiated coverage on Kymera Therapeutics with a new price targetDeutsche Bank initiated coverage of Kymera Therapeutics with a rating of Hold and set a new price target of $120.00
- PRKymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026WATERTOWN, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report second quarter 2026 financial results on August 5, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit "News and Events" in the Investors section of the Company’s website at www.kymeratx.com. A replay of the webcast will be archived and available following the event. About Kymera Therapeutics Kymera is a clinical-stage
- INSIDERChief Medical Officer Rooney Terence was granted 38,000 shares (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERSEC Form 3 filed by new insider Rooney Terence3 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECKymera Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Kymera Therapeutics, Inc. (0001815442) (Filer)
- PRKymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical OfficerDr. Rooney, former immunology leader at Johnson & Johnson, will lead clinical development strategy across Kymera’s industry-leading oral immunology portfolio Jared Gollob, MD, will retire from his role after eight years of leadership at the Company WATERTOWN, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Terence Rooney, MD, as Chief Medical Officer. Dr. Rooney is an accomplished drug development leader with extensive experience advancing immunology therapies across the full developmen
- INSIDERChief Executive Officer Mainolfi Nello exercised 50,000 shares at a strike of $2.08 and sold $5,950,000 worth of shares (50,000 units at $119.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- PRKymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 DegraderDr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera’s KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end 2026 and late 2027, respectively; Phase 3 trials in AD planned to initiate by mid-2027 WATERTOWN, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Elizabeth Laws, Ph.D., as Senior Vice President, KT-621 Development Program Leader. Dr. Laws brings more than two decades of biopharmaceutical leaders
- INSIDERChief Business Officer Goodman Noah sold $387,329 worth of shares (3,389 units at $114.29) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 47,179 units (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERChief Financial Officer Jacobs Bruce N. exercised 61,378 shares at a strike of $5.33 and sold $8,864,829 worth of shares (77,109 units at $114.96) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 244,883 units (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERChief Executive Officer Mainolfi Nello sold $9,223,527 worth of shares (80,000 units at $115.29) as part of a pre-agreed trading plan and exercised 80,000 shares at a strike of $2.08 (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERAmendment: Director Booth Bruce sold $8,281,905 worth of shares (76,650 units at $108.05) as part of a pre-agreed trading plan (SEC Form 4)4/A - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERDirector Booth Bruce sold $3,424,800 worth of shares (31,283 units at $109.48) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- INSIDERDirector Booth Bruce sold $56,460,136 worth of shares (513,245 units at $110.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- INSIDERDirector Bvf Partners L P/Il sold $173,665,077 worth of shares (1,630,658 units at $106.50) (SEC Form 4)4 - Kymera Therapeutics, Inc. (0001815442) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Kymera Therapeutics Inc.SCHEDULE 13D/A - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
- SECSEC Form 144 filed by Kymera Therapeutics Inc.144 - Kymera Therapeutics, Inc. (0001815442) (Subject)
KYMR FAQ
7 questionsWhat does Kymera Therapeutics Inc. do?
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid...Where does KYMR stock trade?
Kymera Therapeutics Inc. (KYMR) is listed on NASDAQ.What sector and industry is KYMR in?
Kymera Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Kymera Therapeutics Inc. go public?
Kymera Therapeutics Inc. (KYMR) completed its IPO in 2020.What are analysts saying about KYMR?
Kymera Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Deutsche Bank: Hold on 2026-07-30.What companies are similar to KYMR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare KYMR side-by-side with any of them on Quantisnow.How can I track KYMR on Quantisnow?
Quantisnow aggregates Kymera Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KYMR to receive live email and push alerts on every new disclosure.